HF
IBRX icon

HRT Financial’s ImmunityBio IBRX Stock Holding History

HRT Financial’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,925,446
Closed -$29.7M – 4722
2026
Q1 		$30.1M Buy
+3,925,446
New +$26.9M 0.08% 227
2025
Q2 		– Sell
-237,761
Closed -$715K – 3054
2025
Q1 		$715K Buy
+237,761
New +$721K ﹤0.01% 1289
2024
Q3 		– Sell
-67,782
Closed -$428K – 2739
2024
Q2 		$428K Buy
+67,782
New +$447K ﹤0.01% 1359
2023
Q2 		– Sell
-69,888
Closed -$127K – 2819
2023
Q1 		$127K Buy
+69,888
New +$217K ﹤0.01% 2018
2022
Q3 		– Sell
-54,717
Closed -$203K – 3112
2022
Q2 		$203K Buy
54,717
+16,875
+45% +$67.8K ﹤0.01% 2237
2022
Q1 		$212K Buy
+37,842
New +$232K ﹤0.01% 2458
2021
Q2 		– Sell
-93,764
Closed -$2.23M – 3141
2021
Q1 		$2.23M Buy
+93,764
New +$2.43M 0.02% 565
2019
Q1 		– Sell
-17,042
Closed -$19K – 647
2018
Q4 		$19K Buy
+17,042
New +$39K ﹤0.01% 553

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HRT Financial's IBRX Position: Q2 2026 in Review

HRT Financial sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 3,925,446 shares — an estimated $29.7M sold.

HRT Financial first reported a position in IBRX in Q4 2018 and held it in 8 quarters. The position peaked at $30.1M in Q1 2026. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • HRT Financial reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 3,925,446 ImmunityBio shares in Q2 2026, an estimated $29.7M.
  • HRT Financial first reported a position in ImmunityBio in Q4 2018 and held it in 8 quarters.
  • HRT Financial's ImmunityBio position peaked at $30.1M in Q1 2026.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.